Health Catalyst, Inc.

NASDAQ:HCAT

Medical - Healthcare Information Services

Healthcare
$1.29 -1.98%

-$0.04 today

Market cap
$98.24M
Beta
1.66
P/E (TTM)
-0.5
EPS (TTM)
-$3.65
52W Low $0.96High $4.13

Volume 0.27M

Average 1.24M

HCAT Purchases of Investments

Cash used to buy marketable securities and other investments.

Health Catalyst, Inc.NASDAQ: HCAT

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments turns negative

Q1 FY2026 purchases of investments was -$24.92M, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was -$90.05M. Over 3 fiscal years it compounded at -40.5% a year.

Context

  • Purchases of investments amounted to 20.9% of revenue in FY2025, down 34.0 pp from a year earlier.
  • Purchases of investments grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly purchases of investments holds near -$24.92M or moves back toward the trailing-twelve-month quarterly average of -$22.51M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$24.92M+215.1% QoQ
Last fiscal yearDec 2025
-$65.13M-61.3% YoY
LTMMar 2026
-$90.05M-23.8% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-61.3%——
3-year CAGR-40.5%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(65.13M) USD
Year-over-year change
+61.3%

Purchases of Investments vs competitors

How HCAT compares with its peers on the latest reported figures

  • HCAT's LTM Mar 2026 purchases of investments of $90.05M is the 5th largest of the 11 companies compared; the peer median is $76.59M.
  • Its year-over-year change of -23.8% is the 6th highest of 9, against a peer median of +64.2%.
  • Purchases of investments amounts to 29.8% of revenue for HCAT, versus a peer median of 195.4%.
HCAT Competitors Peer median
Purchases of Investments for HCAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$345.19M +129.9%+6.9%498.7%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$156.06M -37.3%-23.7%1393.0%
OMOutset Medical, Inc.LTM Mar 2026$148.53M +3812.9%-5.3%126.3%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$91.4M +61.3%-5.4%546.7%
HCATHealth Catalyst, Inc.LTM Mar 2026$90.05M -23.8%-40.5%29.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$86.54M +67.0%+6.3%264.4%
PYXSPyxis Oncology, Inc.LTM Mar 2026$66.65M -43.8%—480.9%
NNOXNano-X Imaging Ltd.LTM Dec 2025$15.91K -100.0%-88.3%0.1%
HSDTSolana CompanyLTM Mar 2026$0 ——0.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$0 +100.0%—0.0%
SNWVSANUWAVE Health, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding HCAT) $76.59M+64.2%-5.3%195.4%

Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(153.21M)(137.4M)(118.15M)(69.5M)(177.97M)
Depreciation & Amortization37.53M48.3M42.22M41.43M50.5M
Deferred Income Tax(7.13M)(4.52M)8K77K81K
Stock-Based Compensation65.15M72.1M55.76M40.13M27.01M
Change in Working Capital4.62M(13.91M)(13.67M)(660K)(15.11M)
Accounts Receivables102K788K(13.66M)4.28M(1.81M)
Inventory(8.33M)0000
Accounts Payables5.2M(4.7M)4.87M5.58M(11.51M)
Other Working Capital7.64M(9.99M)(4.88M)(10.52M)(1.79M)
Other Non-Cash Items29.93M162K750K3.09M116.22M
Operating Cash Flow(23.12M)(35.27M)(33.08M)14.56M731K
Capital Expenditures(18.47M)(17.41M)(14.31M)(16.4M)(968K)
Acquisitions (Net)(46.76M)(27.85M)(11.39M)(80.28M)(41.11M)
Purchases of Investments(261.36M)(308.96M)(290.84M)(168.31M)(65.13M)
Sales of Investments186.89M315.17M336.8M242.07M163.95M
Other Investing Activities22K(15.22M)(13.04M)(14.77M)(20.54M)
Investing Cash Flow(139.68M)(39.02M)20.29M(22.9M)36.19M
Debt Repayment000151.32M(232.29M)
Common Stock Issued245.18M002.58M1.51M
Common Stock Repurchased0(8.39M)(1.81M)0(5M)
Dividends Paid00000
Other Financing Activities18.9M5.78M4.54M(2.15M)0
Financing Cash Flow264.08M(2.61M)2.73M151.75M(235.78M)
Effect of Forex Changes(10K)(11K)21K(34K)27K
Net Change in Cash101.27M(76.92M)(10.04M)143.37M(198.83M)
Free Cash Flow(41.59M)(52.68M)(47.39M)(1.84M)(237K)

Health Catalyst, Inc.

NASDAQ:HCAT

Intrinsic Alpha fair value

Locked

Current Price

$1.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.